95 related articles for article (PubMed ID: 7911613)
1. Somatostatin immunoreactive cells in lesional psoriatic human skin during peptide T treatment.
Johansson O; Hilliges M; Talme T; Marcusson JA; Wetterberg L
Acta Derm Venereol; 1994 Mar; 74(2):106-9. PubMed ID: 7911613
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin- and factor XIIIa-immunoreactive cells in psoriasis during clobetasol propionate and calciprotriol treatment.
Talme T; Schultzberg M; Sundqvist KG; Marcusson JA
Acta Derm Venereol; 1999 Jan; 79(1):44-8. PubMed ID: 10086858
[TBL] [Abstract][Full Text] [Related]
3. Rearrangement of S-100 immunoreactive Langerhans' cells in human psoriatic skin treated with peptide T.
Wang L; Hilliges M; Talme T; Marcusson JA; Wetterberg L; Johansson O
J Dermatol Sci; 1995 Jan; 9(1):20-6. PubMed ID: 7727353
[TBL] [Abstract][Full Text] [Related]
4. Histopathological and immunohistochemical changes in psoriatic skin during peptide T treatment.
Talme T; Rozell BL; Sundqvist KG; Wetterberg L; Marcusson JA
Arch Dermatol Res; 1995; 287(6):553-7. PubMed ID: 7487141
[TBL] [Abstract][Full Text] [Related]
5. Colocalization of somatostatin- and HLA-DR-like immunoreactivity in dendritic cells of psoriatic skin.
Talme T; Schultzberg M; Sundqvist KG; Marcusson JA
Acta Derm Venereol; 1997 Sep; 77(5):338-42. PubMed ID: 9298123
[TBL] [Abstract][Full Text] [Related]
6. Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions.
Chen SC; de Groot M; Kinsley D; Laverty M; McClanahan T; Arreaza M; Gustafson EL; Teunissen MB; de Rie MA; Fine JS; Kraan M
Arch Dermatol Res; 2010 Mar; 302(2):113-23. PubMed ID: 19517126
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1+3, MS-1+/-, 25F9-) in psoriatic dermis.
Djemadji-Oudjiel N; Goerdt S; Kodelja V; Schmuth M; Orfanos CE
Arch Dermatol Res; 1996 Nov; 288(12):757-64. PubMed ID: 8950456
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.
Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Giuliano A; Sabato S; Stramazzotti D; Gulini E; Dusi D; De Blasio S; Fabris G; Offidani A
Int J Immunopathol Pharmacol; 2009; 22(2):371-7. PubMed ID: 19505391
[TBL] [Abstract][Full Text] [Related]
9. Speculations around the mechanism behind the action of peptide T in the healing of psoriasis: a minireview.
Johansson O; Hilliges M; Talme T; Marcusson JA; Wetterberg L
Acta Derm Venereol; 1993 Dec; 73(6):401-3. PubMed ID: 7906447
[TBL] [Abstract][Full Text] [Related]
10. Peptide T improves psoriasis when infused into lesions in nanogram amounts.
Farber EM; Cohen EN; Trozak DJ; Wilkinson DI
J Am Acad Dermatol; 1991 Oct; 25(4):658-64. PubMed ID: 1791224
[TBL] [Abstract][Full Text] [Related]
11. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.
Gilliet M; Conrad C; Geiges M; Cozzio A; Thürlimann W; Burg G; Nestle FO; Dummer R
Arch Dermatol; 2004 Dec; 140(12):1490-5. PubMed ID: 15611427
[TBL] [Abstract][Full Text] [Related]
12. Peptide T a new treatment for psoriasis? A study of nine patients.
Marcusson JA; Talme T; Wetterberg L; Johansson O
Acta Derm Venereol; 1991; 71(6):479-83. PubMed ID: 1685829
[TBL] [Abstract][Full Text] [Related]
13. Decrease in enkephalin levels in psoriatic lesions after calcipotriol and mometasone furoate treatment.
Nissen JB; Avrach WW; Hansen ES; Stengaard-Pedersen K; Kragballe K
Dermatology; 1999; 198(1):11-7. PubMed ID: 10026395
[TBL] [Abstract][Full Text] [Related]
14. Absence of somatostatin receptors in psoriatic skin lesions.
Reubi JC; Hunziker T
Arch Dermatol Res; 1990; 282(2):139-41. PubMed ID: 1972322
[No Abstract] [Full Text] [Related]
15. Expression of p53 protein before and after PUVA treatment in psoriasis.
Hannuksela-Svahn A; Pääkkö P; Autio P; Reunala T; Karvonen J; Vähäkangas K
Acta Derm Venereol; 1999 May; 79(3):195-9. PubMed ID: 10384915
[TBL] [Abstract][Full Text] [Related]
16. Sun exposure rapidly reduces plasmacytoid dendritic cells and inflammatory dermal dendritic cells in psoriatic skin.
Heier I; Søyland E; Krogstad AL; Rodríguez-Gallego C; Nenseter MS; Jahnsen FL
Br J Dermatol; 2011 Oct; 165(4):792-801. PubMed ID: 21623747
[TBL] [Abstract][Full Text] [Related]
17. Effects of [D-Ala1] peptide T-NH2 and HIV envelope glycoprotein gp120 on cyclic AMP dependent protein kinases in normal and psoriatic human fibroblasts.
Liapi C; Takahashi N; Raynaud F; Evain-Brion D; Anderson WB
J Invest Dermatol; 1998 Apr; 110(4):332-7. PubMed ID: 9540970
[TBL] [Abstract][Full Text] [Related]
18. Response of the clinically uninvolved skin of psoriatic patients to tape stripping during acitretin treatment.
Gerritsen MJ; van Pelt JP; van de Kerkhof PC
Acta Derm Venereol; 1996 Jan; 76(1):6-9. PubMed ID: 8721480
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of fluorescence in psoriasis after application of 5-aminolaevulinic acid: an immunohistochemical study.
Kleinpenning MM; Smits T; Ewalds E; van Erp PE; van de Kerkhof PC; Gerritsen MJ
Br J Dermatol; 2006 Sep; 155(3):539-45. PubMed ID: 16911278
[TBL] [Abstract][Full Text] [Related]
20. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation.
Marble DJ; Gordon KB; Nickoloff BJ
J Dermatol Sci; 2007 Nov; 48(2):87-101. PubMed ID: 17689932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
